1343 related articles for article (PubMed ID: 12216105)
1. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
[TBL] [Abstract][Full Text] [Related]
2. Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas.
Felgenhauer J; Hawkins D; Pendergrass T; Lindsley K; Conrad EU; Miser JS
Med Pediatr Oncol; 2000 Jan; 34(1):29-38. PubMed ID: 10611582
[TBL] [Abstract][Full Text] [Related]
3. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: the St. Jude Children's Research Hospital experience.
Navid F; Santana VM; Billups CA; Merchant TE; Furman WL; Spunt SL; Cain AM; Rao BN; Hale GA; Pappo AS
Cancer; 2006 Apr; 106(8):1846-56. PubMed ID: 16541446
[TBL] [Abstract][Full Text] [Related]
4. RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma.
Thomson B; Hawkins D; Felgenhauer J; Radich J
Bone Marrow Transplant; 1999 Sep; 24(5):527-33. PubMed ID: 10482938
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
Pappo AS; Devidas M; Jenkins J; Rao B; Marcus R; Thomas P; Gebhardt M; Pratt C; Grier HE
J Clin Oncol; 2005 Jun; 23(18):4031-8. PubMed ID: 15767644
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas.
Bokemeyer C; Franzke A; Hartmann JT; Schöber C; Arseniev L; Metzner B; Link H; Kanz L; Schmoll HJ
Cancer; 1997 Oct; 80(7):1221-7. PubMed ID: 9317171
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
Schlemmer M; Wendtner CM; Falk M; Abdel-Rahman S; Licht T; Baumert J; Straka C; Hentrich M; Salat C; Hiddemann W; Issels RD
Oncology; 2006; 71(1-2):32-9. PubMed ID: 17344669
[TBL] [Abstract][Full Text] [Related]
8. Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties.
Strauss SJ; McTiernan A; Driver D; Hall-Craggs M; Sandison A; Cassoni AM; Kilby A; Michelagnoli M; Pringle J; Cobb J; Briggs T; Cannon S; Witt J; Whelan JS
J Clin Oncol; 2003 Aug; 21(15):2974-81. PubMed ID: 12885818
[TBL] [Abstract][Full Text] [Related]
9. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
[TBL] [Abstract][Full Text] [Related]
10. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
Miser JS; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Grier HE
J Clin Oncol; 2004 Jul; 22(14):2873-6. PubMed ID: 15254055
[TBL] [Abstract][Full Text] [Related]
11. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experience.
Milano GM; Cozza R; Ilari I; De Sio L; Boldrini R; Jenkner A; De Ioris M; Inserra A; Dominici C; Donfrancesco A
Cancer; 2006 Apr; 106(8):1838-45. PubMed ID: 16532434
[TBL] [Abstract][Full Text] [Related]
12. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.
Wexler LH; DeLaney TF; Tsokos M; Avila N; Steinberg SM; Weaver-McClure L; Jacobson J; Jarosinski P; Hijazi YM; Balis FM; Horowitz ME
Cancer; 1996 Aug; 78(4):901-11. PubMed ID: 8756388
[TBL] [Abstract][Full Text] [Related]
13. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.
Grier HE; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Miser JS
N Engl J Med; 2003 Feb; 348(8):694-701. PubMed ID: 12594313
[TBL] [Abstract][Full Text] [Related]
14. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
Dantonello TM; Int-Veen C; Harms D; Leuschner I; Schmidt BF; Herbst M; Juergens H; Scheel-Walter HG; Bielack SS; Klingebiel T; Dickerhoff R; Kirsch S; Brecht I; Schmelzle R; Greulich M; Gadner H; Greiner J; Marky I; Treuner J; Koscielniak E
J Clin Oncol; 2009 Mar; 27(9):1446-55. PubMed ID: 19224858
[TBL] [Abstract][Full Text] [Related]
15. Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
Lashkari A; Chow WA; Valdes F; Leong L; Phan V; Twardowski P; Kapoor N; Molina A; Al-Kadhimi Z; Frankel P; Somlo G
Anticancer Res; 2009 Aug; 29(8):3281-8. PubMed ID: 19661346
[TBL] [Abstract][Full Text] [Related]
16. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
Patel SR; Papadopolous N; Raymond AK; Donato M; Seong CM; Yasko AW; Lewis VO; Lin PP; Champlin R; Benjamin RS
Cancer; 2004 Jul; 101(1):156-63. PubMed ID: 15222001
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents.
Mora J; de Torres C; Parareda A; Torner F; Galván P; Rodríguez E; Cardesa T; Salvador H; Suñol M; Huguet R; Cruz O
Pediatr Blood Cancer; 2011 Jul; 57(1):69-75. PubMed ID: 21384537
[TBL] [Abstract][Full Text] [Related]
20. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
Kushner BH; Meyers PA; Gerald WL; Healey JH; La Quaglia MP; Boland P; Wollner N; Casper ES; Aledo A; Heller G
J Clin Oncol; 1995 Nov; 13(11):2796-804. PubMed ID: 7595741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
